The case for tailored prostate cancer screening: An NCCN perspective

Michelle L. McDonald, J. Kellogg Parsons

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

A preponderance of clinical evidence supports a significant public health benefit for screening and early detection of prostate cancer in selected men. The challenge lies in maximizing early diagnosis of potentially aggressive but curable disease while minimizing diagnosis and treatment of indolent disease. A tailored approach to population screening in appropriately counseled men, using an evidence-based strategy with judicious prostate-specific antigen (PSA) testing, will reduce prostate-cancer mortality yet limit overdetection of clinically insignificant disease. Use of newer biomarkers that increase specificity for prostate cancer detection, including percentage of free PSA, 4Kscore, prostate health index, prostate cancer antigen 3, and multiparametric MRI may be considered under certain circumstances.

Original languageEnglish (US)
Pages (from-to)1576-1583
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'The case for tailored prostate cancer screening: An NCCN perspective'. Together they form a unique fingerprint.

Cite this